Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program

BACKGROUND: Ozanimod, an oral sphingosine 1-phosphate receptor modulator currently approved for the treatment of moderately to severely active ulcerative colitis and relapsing multiple sclerosis, showed clinical, endoscopic, and histological benefit in the phase 2 STEPSTONE trial for Crohn's di...

Descripción completa

Detalles Bibliográficos
Autores principales: Feagan, Brian G., Schreiber, Stefan, Afzali, Anita, Rieder, Florian, Hyams, Jeffrey, Kollengode, Kanthi, Pearlman, Jared, Son, Vladimir, Marta, Cecilia, Wolf, Douglas C., D'Haens, Geert G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008122/
https://www.ncbi.nlm.nih.gov/pubmed/36208720
http://dx.doi.org/10.1016/j.cct.2022.106958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008122/
https://www.ncbi.nlm.nih.gov/pubmed/36208720
http://dx.doi.org/10.1016/j.cct.2022.106958

Ejemplares similares